Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

Emanuele Rando; Francesco Vladimiro Segala; Joel Vargas; Cristina Seguiti; Gennaro De Pascale; Rita Murri; Massimo Fantoni

doi:10.3390/antibiotics11010003

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

Antibiotics (Basel). 2021 Dec 21;11(1):3. doi: 10.3390/antibiotics11010003.

Authors

Emanuele Rando¹, Francesco Vladimiro Segala^{1

2}, Joel Vargas³, Cristina Seguiti^{1

2}, Gennaro De Pascale³, Rita Murri^{1

2}, Massimo Fantoni^{1

2}

Affiliations

¹ Clinic of Infectious Diseases, Catholic University of the Sacred Heart, 00168 Rome, Italy.
² Department of Laboratory and Infectious Diseases Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
³ Department of Emergency, Anesthesiological and Reanimation Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.

Abstract

Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospectively included patients with CRAB pneumonia hospitalized at Fondazione Policlinico Universitario Agostino Gemelli Hospital treated with cefiderocol either in the general ward or the intensive care unit. A total of 11 patients out of 13 had ventilator-associated pneumonia caused by CRAB, and 12/13 patients had polymicrobial infection. We found a 30-day success rate of 54%. Cefiderocol may have a role when facing severe XDR A. baumannii pneumonia. Future studies are warranted to better define its place in therapy in CRAB infections.

Keywords: A. baumannii; CRAB; cefiderocol; pneumonia.